Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PROMOSTEM is an allogeneic cell therapy consisting of mesenchymal stem cells (MSCs) derived from human umbilical cord blood (UCB). Developed by Samsung Medical Center in collaboration with Medipost, it is specifically designed for the treatment of steroid-refractory acute and chronic graft-versus-host disease (GVHD). MSCs possess potent immunomodulatory properties, enabling them to suppress the activation and proliferation of alloreactive T-cells and modulate the inflammatory environment through the secretion of various soluble factors such as prostaglandin E2 (PGE2) and indoleamine 2,3-dioxygenase (IDO). As a UCB-derived product, PROMOSTEM offers an "off-the-shelf" therapeutic option that does not require stringent HLA matching and can be expanded in vitro for clinical use, providing a significant advantage over bone marrow-derived alternatives in pediatric and adult populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PROMOSTEM (Samsung Medical Center).